{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:25:10Z","timestamp":1794918310884,"version":"4.9.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T00:00:00Z","timestamp":1640476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.biopha.2021.112606","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T19:48:35Z","timestamp":1640634515000},"page":"112606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5\/6 nephrectomised rats on high salt diet"],"prefix":"10.1016","volume":"146","author":[{"given":"Shufei","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Delic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingquan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M.S.","family":"Gaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaochen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Stadermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Frankenreiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard K.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Hocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biopha.2021.112606_bib1","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00125-018-4678-z","article-title":"SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases","volume":"61","author":"Wanner","year":"2018","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.biopha.2021.112606_bib2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"issue":"22","key":"10.1016\/j.biopha.2021.112606_bib3","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.112606_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.112606_bib5","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00210-018-1544-y","article-title":"Empagliflozin, SGLT2 inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: potential role of klotho expression","volume":"391","author":"Abbas","year":"2018","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2021.112606_bib6","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur. J. Heart Fail"},{"issue":"21","key":"10.1016\/j.biopha.2021.112606_bib7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Investigators, dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.biopha.2021.112606_bib8","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","article-title":"Effects of dapagliflozin in DAPA-HF according to background heart failure therapy","volume":"41","author":"Docherty","year":"2020","journal-title":"Eur. Heart J."},{"issue":"10254","key":"10.1016\/j.biopha.2021.112606_bib9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.biopha.2021.112606_bib10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"10.1016\/j.biopha.2021.112606_bib11","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40264-020-01010-6","article-title":"Potential Safety issues with use of sodium-glucose cotransporter 2 inhibitors, particularly in people with type 2 diabetes and chronic kidney disease","volume":"43","author":"Milder","year":"2020","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.biopha.2021.112606_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14740338.2019.1602116","article-title":"An update on the safety of SGLT2 inhibitors","volume":"18","author":"Scheen","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.biopha.2021.112606_bib13","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.kint.2016.01.016","article-title":"The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5\/6 nephrectomy","volume":"89","author":"Tsuprykov","year":"2016","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.biopha.2021.112606_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.biopha.2021.112606_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4663","article-title":"A new HPLC-MS\/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers","volume":"33","author":"Dias","year":"2019","journal-title":"Biomed. Chromatogr."},{"issue":"3","key":"10.1016\/j.biopha.2021.112606_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.kint.2018.03.006","article-title":"AMP-activated kinase is a regulator of fibroblast growth factor 23 production","volume":"94","author":"Glosse","year":"2018","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.biopha.2021.112606_bib17","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.kint.2019.01.010","article-title":"Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5\/6 nephrectomy","volume":"95","author":"Hasan","year":"2019","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.biopha.2021.112606_bib18","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1038\/s41598-020-60336-4","article-title":"Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5\/6 nephrectomy","volume":"10","author":"Delic","year":"2020","journal-title":"Sci. Rep."},{"issue":"43","key":"10.1016\/j.biopha.2021.112606_bib19","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"W1","key":"10.1016\/j.biopha.2021.112606_bib20","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.biopha.2021.112606_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1463-1326.2012.01569.x","article-title":"Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus","volume":"14","author":"Luippold","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2021.112606_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/DMSO.S58786","article-title":"Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet","volume":"7","author":"Vickers","year":"2014","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"Suppl 11","key":"10.1016\/j.biopha.2021.112606_bib23","first-page":"8S","article-title":"SGLT2 Inhibitors for Type 2 diabetes mellitus treatment","volume":"32","author":"Plodkowski","year":"2015","journal-title":"Fed. Pr."},{"issue":"3","key":"10.1016\/j.biopha.2021.112606_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2133\/dmpk.DMPK-12-RG-082","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects","volume":"28","author":"Sarashina","year":"2013","journal-title":"Drug Metab. Pharm."},{"key":"10.1016\/j.biopha.2021.112606_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.redox.2017.11.014","article-title":"The NADPH organizers NoxO1 and p47phox are both mediators of diabetes-induced vascular dysfunction in mice","volume":"15","author":"Rezende","year":"2018","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2021.112606_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101330","article-title":"Differential contribution of Nox1, Nox2 and Nox4 to kidney vascular oxidative stress and endothelial dysfunction in obesity","volume":"28","author":"Munoz","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2021.112606_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/DMSO.S233538","article-title":"Extraglycemic effects of SGLT2 Inhibitors: a review of the evidence","volume":"13","author":"Bonora","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"4","key":"10.1016\/j.biopha.2021.112606_bib28","first-page":"2801","article-title":"Novel compound heterozygous mutations in the SPTA1 gene, causing hereditary spherocytosis in a neonate with coombsnegative hemolytic jaundice","volume":"19","author":"Wang","year":"2019","journal-title":"Mol. Med Rep."},{"issue":"22","key":"10.1016\/j.biopha.2021.112606_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010690","article-title":"Role of ADTRP (androgen-dependent tissue factor pathway inhibitor regulating protein) in vascular development and function","volume":"7","author":"Patel","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.biopha.2021.112606_bib30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1152\/physiolgenomics.00028.2016","article-title":"Coronary artery disease susceptibility gene ADTRP regulates cell cycle progression, proliferation, and apoptosis by global gene expression regulation","volume":"48","author":"Luo","year":"2016","journal-title":"Physiol. Genom."},{"issue":"1","key":"10.1016\/j.biopha.2021.112606_bib31","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1038\/s41598-020-64201-2","article-title":"Caloric restriction reverses left ventricular hypertrophy through the regulation of cardiac iron homeostasis in impaired leptin signaling mice","volume":"10","author":"An","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2021.112606_bib32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112606_bib33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-021-01322-6","article-title":"The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats","volume":"20","author":"Daud","year":"2021","journal-title":"Cardiovasc Diabetol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221013937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221013937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:47:04Z","timestamp":1779965224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221013937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":33,"alternative-id":["S0753332221013937"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112606","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5\/6 nephrectomised rats on high salt diet","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112606"}}